Chaperone Technologies, Inc'

1
Chaperone Technologies, Inc.

• Novel Antimicrobials for Multi-Drug Resistance

2
Chaperone Technologies

• Developing novel antimicrobials,
• based on a proprietary mechanism of
• action, for difficult-to-treat
• and drug-resistant organisms

3
Antimicrobials Market Opportunity

• 27.0BB global market
• Explosive growth of drug resistant organisms
• All current antimicrobials have varying
  resistance

4
Near-Term Potential

• Lead compound for complicated urinarytract
  infection
• 2.0BB global market
• Kills drug-resistant UTI organisms
• First IND in the next 12-24 months

5
Investment Rationale

• Novel proprietary DnaK inhibition platform
• Proven in vivo in vitro activity
• Broad, sustainable, pipeline of human
• and non-human applications with large market
  values
• Multiple partnering opportunities

6
DnaK Inhibition

• DnaK
• Intracellular target
• Controls protein folding
• Present for all organisms
• Pyrrhocorocin
• Natural insect antimicrobial
• Most active natural peptide
• Lead peptide is analog

7
Lead Peptide
Proven ability to kill ?-lactam, tetracycline,
aminoglycoside, TMP-SMX resistant strains

• Escherichia coli
• Klebsiella pneumoniae
• Moraxella catarrhalis
• Salmonella typhimurium
• Pseudomonas aeruginosa
• Haemophilus influenzae
• Agrobacterium tumefaciens
• Staphylococcus aureus

8
Why CHP-105?

• Kills major drug-resistant UTI pathogens
• 2.0BB market
• Parenteral or oral delivery
• Does not
• Bind to human cells
• Lyse cell walls
• Not subject to genetic variation

9
Value Creation
New Business
Core Business Growth
Technology Leadership

• Topicals
• Antifungals
• Antiparasitics
• Agriculture
• Biopesticides
• Biodefense
• Drug delivery

Value creation

• Respiratory Infections
• Gastrointestinal Infections
• Other AI
• Aquaculture

• Urinary Tract Infections
• DnaK screening

Long Term (Total Market gt40B)
Medium Term (Total Market gt24B)
Short Term (Total Market 2BB)
10
Strategy
Repository for DnaK Inhibiton
Retain US rights-- niche product applications
Outlicensenon-strategicapplications
Expand DnaK platform(partner in early
development)
CHP-105 in UTI
11
Recent Accomplishments

• Publications in six peer-reviewed scientific
  journals
• Submission / approval of multiple SBIR grants
• Collaboration with the Marine Biology Laboratory
  on expanded applications

12
Use of Funds

• CHP-105 further development in UTI
• Expand DnaK platform
• Expand drug development expertise

13
Summary

• Novel platform
• Proven activity
• Broad sustainable pipeline
• Multiple partnering opportunities